RT Journal Article
SR Electronic
T1 A flexible COVID-19 model to assess mitigation, “reopening”, virus mutation and other changes
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.09.20150029
DO 10.1101/2020.07.09.20150029
A1 Bienstock, Sergio
YR 2020
UL http://medrxiv.org/content/early/2020/07/11/2020.07.09.20150029.abstract
AB The COVID-19 epidemic which began in China last year has expanded worldwide. A flexible SEIRD epidemiological model with time-dependent parameters is applied to modeling the pandemic. The value of the effective reproduction ratio is varied to quantify the impact of quarantines and social distancing on the number of infections and deaths, on their daily changes. and on the maxima in these daily rates expected during the epidemic. The effect of changing Reff is substantial. It ought to inform policy decisions around resource allocation, mitigation strategies and their duration, and economic tradeoffs. The model can also calculate the impact of changes in infectiousness or morbidity as the virus mutates, or the expected effects of a new therapy or vaccine assumed to arrive at a future date. The paper concludes with a discussion of a potential endemic end of COVID-19, which might involve times of about 100 years.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding supported this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not applicable.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred to in the manuscript has been published.